MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib
By Dr. Abdulraheem Yacoub
Dr. Abdulraheem Yacoub discusses with OncologyTube the ASH 2022 abstract, he included the presentation and slides. The MPN (myeloproliferative neoplasm) Study, in which Parsaclisib was administered in addition to Ruxolitinib treatment, has just lately come to a conclusion. Following the completion of the second part of the clinical trial, these are the final findings about the effectiveness and safety of the treatment. Patients who were diagnosed with anemia, regardless of whether or not they were in need of blood transfusions, were given the opportunity to take part in the study. Patients were able to participate in the research even if their platelet count was as low as 50,000 if they met certain criteria. Patients were allowed to participate in the trial even if they had a hemoglobin level that was below the minimum requirement. The key finding was that there was a considerable decrease in clinic volume at week 12 as determined by imaging, and this decline was noteworthy. The primary endpoint assessment was completed by 66 patients, which represents 89 percent of the total number of patients. In addition, there are 31 people who have been a member of a study for longer than a year, which provides additional evidence that the combination that is being researched is safe.
Patients who had been taking Ruxolitinib prior to receiving Parsaclisib experienced a further reduction in standard volume at week 12 and at week 24 as a result of the combination therapy. This was the case for both of the patient groups. There were not many treatment-emergent adverse events that met the criteria to be considered serious.
Watch and Share the Video Here: https://oncologytube.com/v/41723
Read and Share the Article Here: https://oncologytube.com/v/41724
Listen and Share the Audio Podcast Here: https://oncologytube.com/v/41725
